DRW Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

DRW Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-10,000	Closed	-$947K	–	136
2014 Q2	$947K	Buy	+10,000	New	+$701K	0.17%	56

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DRW Securities's VRTX Position: Q1 2026 in Review

DRW Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 746 shares — an estimated $335K sold.

DRW Securities first reported a position in VRTX in Q2 2015 and held it in 10 quarters. The position peaked at $10.2M in Q2 2015. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

DRW Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 746 Vertex Pharmaceuticals shares in Q1 2026, an estimated $335K.
DRW Securities first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 10 quarters.
DRW Securities's Vertex Pharmaceuticals position peaked at $10.2M in Q2 2015.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.